Date: <u>February 20, 2022</u> Your Name: <u>Duan Zhu</u>

Manuscript Title: The downregulation of miR-129-5p relieves the inflammatory response in ARDS by

regulating PPARy-mediated autophagy

Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | the General project of National Natural Science Foundation of China (project No. 81670070) Chongqing Research Program of Basic Research and Frontier Technology (project No. cstc2017jcyjAX0338) | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | | |
| 3 | Royalties or licenses | | |
| 4 | Consulting fees | _ | |

| | | √None | |
|----|------------------------------|--------|--|
| 5 | Payment or honoraria for | | |
| | lectures, presentations, | | |
| | speakers bureaus, | √None | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | | |
| | testimony | | |
| | | √None | |
| 7 | Support for attending | | |
| | meetings and/or travel | | |
| | | | |
| | | √None | |
| 8 | Patents planned, issued or | | |
| 0 | pending | | |
| | perianig | √ None | |
| 9 | Participation on a Data | | |
| , | Safety Monitoring Board or | | |
| | Advisory Board | √ None | |
| 10 | Leadership or fiduciary role | VNone | |
| 10 | in other board, society, | | |
| | committee or advocacy | √ None | |
| | group, paid or unpaid | None | |
| 11 | Stock or stock options | | |
| | Stock of Stock options | | |
| | | √ None | |
| 12 | Receipt of equipment, | | |
| 12 | materials, drugs, medical | | |
| | writing, gifts or other | √ None | |
| | services | | |
| 13 | Other financial or non- | | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| D! | | | |

| The author reports that this study received funding from the General project of National Natural Science | e Foundation |
|--|--------------|
| of China (project No. 81670070), and the Chongqing Research Program of Basic Research and Frontier T | echnology |
| (project No. cstc2017jcyjAX0338). | |
| | |

Please place an "" next to the following statement to indicate your agreement:

Date: <u>February 20, 2022</u> Your Name: <u>Mi Zhou</u>

Manuscript Title: The downregulation of miR-129-5p relieves the inflammatory response in ARDS by

regulating PPARy-mediated autophagy

Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work | |
|---|---|--|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | the General project of National Natural Science Foundation of China (project No. 81670070) Chongqing Research Program of Basic Research and Frontier Technology (project No. cstc2017jcyjAX0338) | | |
| | | Time frame: past | 36 months | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | | | |
| 3 | Royalties or licenses | | | |
| 4 | Consulting fees | _ | | |

| | | √None | |
|----|------------------------------|--------|--|
| 5 | Payment or honoraria for | | |
| | lectures, presentations, | | |
| | speakers bureaus, | √ None | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | | |
| | testimony | | |
| | | √None | |
| 7 | Support for attending | | |
| | meetings and/or travel | | |
| | | | |
| | | √ None | |
| | | | |
| 8 | Patents planned, issued or | | |
| | pending | | |
| | | None | |
| 9 | Participation on a Data | | |
| | Safety Monitoring Board or | | |
| | Advisory Board | √None | |
| 10 | Leadership or fiduciary role | | |
| | in other board, society, | | |
| | committee or advocacy | √None | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | | |
| | | | |
| | | √None | |
| 12 | Receipt of equipment, | | |
| | materials, drugs, medical | | |
| | writing, gifts or other | √None | |
| | services | | |
| 13 | Other financial or non- | | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |

| The author reports that this study received funding from the General project of National Natural Science Foundation |
|---|
| of China (project No. 81670070), and the Chongqing Research Program of Basic Research and Frontier Technology |
| (project No. cstc2017jcyjAX0338). |
| |

Please place an "" next to the following statement to indicate your agreement:

Date: <u>February 20, 2022</u> Your Name: <u>Kang Wang</u>

Manuscript Title: The downregulation of miR-129-5p relieves the inflammatory response in ARDS by

regulating PPARy-mediated autophagy

Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this | Specifications/Comments (e.g., if payments were made to you or to your |
|---|--|--|--|
| | | relationship or indicate none (add rows as | institution) |
| | | needed) | |
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, | the General project of National Natural Science Foundation of China (project No. 81670070) | |
| | provision of study materials, medical writing, article processing charges, etc.) | Chongqing Research Program of Basic Research and Frontier Technology (project No. cstc2017jcyjAX0338) | |
| | No time limit for this item. | CStC2017jCyjAX0536j | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | , | |
| | in item #1 above). | √None | |
| 3 | Royalties or licenses | | |
| | | √None | |
| 4 | Consulting fees | | |

| | | √None | |
|----|------------------------------|--------|--|
| 5 | Payment or honoraria for | | |
| | lectures, presentations, | | |
| | speakers bureaus, | √ None | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | | |
| | testimony | | |
| | | √None | |
| 7 | Support for attending | | |
| | meetings and/or travel | | |
| | | | |
| | | √ None | |
| | | | |
| 8 | Patents planned, issued or | | |
| | pending | | |
| | | None | |
| 9 | Participation on a Data | | |
| | Safety Monitoring Board or | | |
| | Advisory Board | √None | |
| 10 | Leadership or fiduciary role | | |
| | in other board, society, | | |
| | committee or advocacy | √None | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | | |
| | | | |
| | | √None | |
| 12 | Receipt of equipment, | | |
| | materials, drugs, medical | | |
| | writing, gifts or other | √None | |
| | services | | |
| 13 | Other financial or non- | | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |

| The author reports that this study received funding from the General project of National Natural Science Foundation |
|---|
| of China (project No. 81670070), and the Chongqing Research Program of Basic Research and Frontier Technology |
| (project No. cstc2017jcyjAX0338). |
| |

Please place an "" next to the following statement to indicate your agreement:

Date: <u>February 20, 2022</u> Your Name: <u>Xueting Hu</u>

Manuscript Title: The downregulation of miR-129-5p relieves the inflammatory response in ARDS by

regulating PPARy-mediated autophagy

Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | the General project of National Natural Science Foundation of China (project No. 81670070) Chongqing Research Program of Basic Research and Frontier Technology (project No. cstc2017jcyjAX0338) | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | | |
| 3 | Royalties or licenses | | |
| 4 | Consulting fees | | |

| | | √None | |
|----|------------------------------|--------|--|
| 5 | Payment or honoraria for | | |
| | lectures, presentations, | | |
| | speakers bureaus, | √ None | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | | |
| | testimony | | |
| | | √None | |
| 7 | Support for attending | | |
| | meetings and/or travel | | |
| | | | |
| | | √ None | |
| | | | |
| 8 | Patents planned, issued or | | |
| | pending | | |
| | | None | |
| 9 | Participation on a Data | | |
| | Safety Monitoring Board or | | |
| | Advisory Board | √None | |
| 10 | Leadership or fiduciary role | | |
| | in other board, society, | | |
| | committee or advocacy | √None | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | | |
| | | | |
| | | √None | |
| 12 | Receipt of equipment, | | |
| | materials, drugs, medical | | |
| | writing, gifts or other | √None | |
| | services | | |
| 13 | Other financial or non- | | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |

| The author reports that this study received funding from the General project of National Natural Science Foundation |
|---|
| of China (project No. 81670070), and the Chongqing Research Program of Basic Research and Frontier Technology |
| (project No. cstc2017jcyjAX0338). |
| |

Please place an "" next to the following statement to indicate your agreement:

Date: <u>February 20, 2022</u> Your Name: <u>Liang Gong</u>

Manuscript Title: The downregulation of miR-129-5p relieves the inflammatory response in ARDS by

regulating PPARy-mediated autophagy

Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | the General project of National Natural Science Foundation of China (project No. 81670070) Chongqing Research Program of Basic Research and Frontier Technology (project No. cstc2017jcyjAX0338) | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | | |
| 3 | Royalties or licenses | | |
| 4 | Consulting fees | | |

| | | √None | |
|----|------------------------------|--------|--|
| 5 | Payment or honoraria for | | |
| | lectures, presentations, | | |
| | speakers bureaus, | √ None | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | | |
| | testimony | | |
| | | √None | |
| 7 | Support for attending | | |
| | meetings and/or travel | | |
| | | | |
| | | √ None | |
| | | | |
| 8 | Patents planned, issued or | | |
| | pending | | |
| | | None | |
| 9 | Participation on a Data | | |
| | Safety Monitoring Board or | | |
| | Advisory Board | √None | |
| 10 | Leadership or fiduciary role | | |
| | in other board, society, | | |
| | committee or advocacy | √None | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | | |
| | | | |
| | | √None | |
| 12 | Receipt of equipment, | | |
| | materials, drugs, medical | | |
| | writing, gifts or other | √None | |
| | services | | |
| 13 | Other financial or non- | | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |

| The author reports that this study received funding from the General project of National Natural Science Foundation |
|---|
| of China (project No. 81670070), and the Chongqing Research Program of Basic Research and Frontier Technology |
| (project No. cstc2017jcyjAX0338). |
| |

Please place an "" next to the following statement to indicate your agreement:

Date: <u>February 20, 2022</u> Your Name: <u>Hu Luo</u>

Manuscript Title: The downregulation of miR-129-5p relieves the inflammatory response in ARDS by

regulating PPARy-mediated autophagy

Manuscript number (if known):_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | the General project of National Natural Science Foundation of China (project No. 81670070) Chongqing Research Program of Basic Research and Frontier Technology (project No. cstc2017jcyjAX0338) | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | | |
| 3 | Royalties or licenses | | |
| 4 | Consulting fees | | |

| | | √None | |
|----|------------------------------|--------|--|
| 5 | Payment or honoraria for | | |
| | lectures, presentations, | | |
| | speakers bureaus, | √ None | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | | |
| | testimony | | |
| | | √None | |
| 7 | Support for attending | | |
| | meetings and/or travel | | |
| | | | |
| | | √ None | |
| | | | |
| 8 | Patents planned, issued or | | |
| | pending | | |
| | | None | |
| 9 | Participation on a Data | | |
| | Safety Monitoring Board or | | |
| | Advisory Board | √None | |
| 10 | Leadership or fiduciary role | | |
| | in other board, society, | | |
| | committee or advocacy | √None | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | | |
| | | | |
| | | √None | |
| 12 | Receipt of equipment, | | |
| | materials, drugs, medical | | |
| | writing, gifts or other | √None | |
| | services | | |
| 13 | Other financial or non- | | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |

| The author reports that this study received funding from the General project of National Natural Science Foundation |
|---|
| of China (project No. 81670070), and the Chongqing Research Program of Basic Research and Frontier Technology |
| (project No. cstc2017jcyjAX0338). |
| |

Please place an "" next to the following statement to indicate your agreement:

Date: <u>February 20, 2022</u> Your Name: <u>Xiangdong Zhou</u>

Manuscript Title: The downregulation of miR-129-5p relieves the inflammatory response in ARDS by

regulating PPARy-mediated autophagy

Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Whom you have this relationship or indicate institution) (e.g., if payments were made to you or to your institution) (head rows as needed) Time frame: Since the initial planning of the work the General project of National Natural Science Foundation of China (project No. 81670070) Chongqing Research Program of Basic Research and Frontier Technology (project No. cstc2017jcyjAX0338) Time frame: past 36 months 2 Grants or contracts from | | relationship or indicate institution) | |
|---|----------|--|-----------------------------|
| none (add rows as needed) Time frame: Since the initial planning of the work 1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. No time limit for this item. No time limit for this item. none (add rows as needed) Time frame: planning of the work the General project of National Natural Science Foundation of China (project No. 81670070) Chongqing Research Program of Basic Research and Frontier Technology (project No. cstc2017jcyjAX0338) Time frame: past 36 months | <u>■</u> | | |
| Time frame: Since the initial planning of the work 1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: Since the initial planning of the work the General project of National Natural Science Foundation of China (project No. 81670070) Chongqing Research Program of Basic Research and Frontier Technology (project No. cstc2017jcyjAX0338) Time frame: past 36 months | | none (add rows as | |
| Time frame: Since the initial planning of the work 1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: Since the initial planning of the work the General project of National Natural Science Foundation of China (project No. 81670070) Chongqing Research Program of Basic Research and Frontier Technology (project No. cstc2017jcyjAX0338) Time frame: past 36 months | | none (add rows as | |
| All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months | | needed) | |
| manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Natural Science Foundation of China (project No. 81670070) Chongqing Research Program of Basic Research and Frontier Technology (project No. cstc2017jcyjAX0338) Time frame: past 36 months | | Time frame: Since the initial planning of the work | |
| medical writing, article processing charges, etc.) No time limit for this item. Basic Research and Frontier Technology (project No. cstc2017jcyjAX0338) Time frame: past 36 months | _ | Natural Science Foundation of China (project No. 81670070) | manuscript (e.g., funding, |
| Processing charges, etc.) No time limit for this item. Technology (project No. cstc2017jcyjAX0338) Time frame: past 36 months | | | 1 - |
| No time limit for this item. Time frame: past 36 months | | Technology (project No. | _ |
| Time frame: past 36 months | _ | oscezo 17 jej i miosoo j | |
| | | | No time mint for this iter |
| | | | |
| | | | |
| 2 Grants or contracts from | | Time frame: past 36 months | |
| | | | 2 Grants or contracts from |
| any entity (if not indicated | | ed | any entity (if not indicate |
| in item #1 above)None | | | in item #1 above). |
| 3 Royalties or licenses | | | Royalties or licenses |
| | | | |
| | | | |
| 4 Consulting fees | | | Consulting fees |

| | | √None | |
|----|------------------------------|--------|--|
| 5 | Payment or honoraria for | | |
| | lectures, presentations, | | |
| | speakers bureaus, | √ None | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | | |
| | testimony | | |
| | | √None | |
| 7 | Support for attending | | |
| | meetings and/or travel | | |
| | | | |
| | | √ None | |
| | | | |
| 8 | Patents planned, issued or | | |
| | pending | | |
| | | None | |
| 9 | Participation on a Data | | |
| | Safety Monitoring Board or | | |
| | Advisory Board | √None | |
| 10 | Leadership or fiduciary role | | |
| | in other board, society, | | |
| | committee or advocacy | √None | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | | |
| | | | |
| | | √None | |
| 12 | Receipt of equipment, | | |
| | materials, drugs, medical | | |
| | writing, gifts or other | √None | |
| | services | | |
| 13 | Other financial or non- | | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |

| The author reports that this study received funding from the General project of National Natural Science Foundation |
|---|
| of China (project No. 81670070), and the Chongqing Research Program of Basic Research and Frontier Technology |
| (project No. cstc2017jcyjAX0338). |
| |

Please place an "" next to the following statement to indicate your agreement:

Date: <u>February 20, 2022</u> Your Name: <u>Jianlin Hu</u>

Manuscript Title: The downregulation of miR-129-5p relieves the inflammatory response in ARDS by

regulating PPARy-mediated autophagy

Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with | Specifications/Comments | 1 |
|---|-------------------------------|---|--|---|
| | | whom you have this | (e.g., if payments were made to you or to your | |
| | | relationship or indicate | institution) | |
| | | - | institution) | |
| | | none (add rows as | | |
| | | needed) | | |
| | | Time frame: Since the initial | planning of the work | |
| 1 | All support for the present | the General project of National | | |
| | manuscript (e.g., funding, | Natural Science Foundation of China (project No. 81670070) | | |
| | provision of study materials, | Chongqing Research Program of | | 1 |
| | medical writing, article | Basic Research and Frontier | | |
| | processing charges, etc.) | Technology (project No. | | |
| | No time limit for this item. | cstc2017jcyjAX0338) | | - |
| | No time limit for this item. | | | |
| | | | | 1 |
| | | | | 1 |
| | | Time a function to the | 2C | |
| | | Time frame: past | 36 months | |
| 2 | Grants or contracts from | | | |
| | any entity (if not indicated | | | |
| | in item #1 above). | √None | | |
| 3 | Royalties or licenses | | | |
| | | | | |
| | | √None | | |
| 4 | Consulting fees | - | | 1 |
| | = | | | 1 |

| | | √None | |
|----|------------------------------|--------|--|
| 5 | Payment or honoraria for | | |
| | lectures, presentations, | | |
| | speakers bureaus, | √ None | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | | |
| | testimony | | |
| | | √None | |
| 7 | Support for attending | | |
| | meetings and/or travel | | |
| | | | |
| | | √ None | |
| | | | |
| 8 | Patents planned, issued or | | |
| | pending | | |
| | | None | |
| 9 | Participation on a Data | | |
| | Safety Monitoring Board or | | |
| | Advisory Board | √None | |
| 10 | Leadership or fiduciary role | | |
| | in other board, society, | | |
| | committee or advocacy | √None | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | | |
| | | | |
| | | √None | |
| 12 | Receipt of equipment, | | |
| | materials, drugs, medical | | |
| | writing, gifts or other | √None | |
| | services | | |
| 13 | Other financial or non- | | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |

| The author reports that this study received funding from the General project of National Natural Science Foundation |
|---|
| of China (project No. 81670070), and the Chongqing Research Program of Basic Research and Frontier Technology |
| (project No. cstc2017jcyjAX0338). |
| |

Please place an "" next to the following statement to indicate your agreement: